A study of the prevalence and treatment of psoriasis in older Americans suggests the presence of economic and racial barriers.
A study of the prevalence and treatment of psoriasis in older Americans suggests the presence of economic and racial barriers, according to a study published in the Journal of Investigative Dermatology.
Researchers from the Perelman School of Medicine at the University of Pennsylvania analyzed the prevalence of psoriasis and its treatments, focusing on biologics and their use, among Medicare beneficiaries.
Only 27% of the total population studied had moderate to severe psoriasis, and just 10% of all patients studied were receiving biologics. Although 7.5 million Americans are affected by psoriasis, a prevalence rate of 2% to 4%, the researchers determined the prevalence of medical claims for the disease ranged from just 0.51% to 1.23%.
“Previous studies have shown that psoriasis is associated with major physical and psychosocial health burdens that increase proportionally with more severe disease,” lead author Junko Takeshita, MD, PhD, a dermatologist at Penn Medicine, said in a statement. “Although the biologics are generally regarded as being highly effective treatments for patients with moderate or severe psoriasis, our results suggest that out-of-pocket costs and race may impact who receives these treatments.”
The researchers found that patients with a Medicare Part D low-income subsidy were 70% less likely to receive biologics than patients with the low-income subsidy. Black patients were 69% less likely than white patients to receive biologics.
“Future studies are needed to determine if these barriers exist among psoriasis patients with Medicaid or private insurance,” said senior author Jalpa A. Doshi, PhD, associate professor of Medicine at the Perelman School of Medicine. “Additionally, further study should focus specifically on identifying the causes of such barriers, whether they are patient-centric variables such as treatment preferences and varying levels of understanding the disease, or physician factors including the frequency with which certain treatments are being offered.”
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More